TETRA Technologies Inc.

1 month ago · seekingalpha.com

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript

2 months ago · zacks.com

Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

2 months ago · seekingalpha.com

TETRA Technologies, Inc. (TTI) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Tetra Technologies (TTI) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

2 months ago · zacks.com

Although the revenue and EPS for Tetra Technologies (TTI) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

2 months ago · prnewswire.com

SPRING, Texas, Aug. 3, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three and six months ended June 30, 2026. Second-Quarter 2026 Financial Highlights Revenues of $185.7 million Income from continuing operations of $10.2 million, inclusive of $1.1 million of unusual charges Adjusted EBITDA of $31.9 million Net Income per share from continuing operations of $0.07, adjusted net income per share of $0.08 Launched TETRA Neptune Z-Lite, awarded a three-well Gulf of America Deepwater Project Raised $108 million of net proceeds related to the equity offering Board of Directors approved final investment decision ("FID") for the Arkansas Bromine Project Brady Murphy, TETRA's President and Chief Executive Officer, stated, "We delivered one of our strongest second-quarter and first-half financial performances in the past decade, reflecting the strength of our base business and our ability to grow in deepwater and international markets.

2 months ago · globenewswire.com

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

2 months ago · zacks.com

Tetra Technologies (TTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · prnewswire.com

SPRING, Texas, July 13, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE:TTI) will release Second Quarter 2026 results after the market closes on August 3, 2026 and will host a conference call to discuss the results and outlook on August 4, 2026, at 10:30am ET. CLICK HERE to pre-register and obtain your dial in number and passcode.

2 months ago · newsfilecorp.com

San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing novel sulfur-based thiol therapies for rare pediatric, metabolic and mitochondrial disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age.